MedTrace Logo

Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

NCT02453386 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 449

Last updated 2019-04-03

Study results available
· View outcomes & findings →

Summary

Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm safety and efficacy study (Part A) with an open-label phase (Part B).

Conditions

  • Idiopathic Parkinson's Disease

Interventions

DRUG

tozadenant

DRUG

placebo

Sponsors & Collaborators

  • Biotie Therapies Inc.

    lead INDUSTRY

Principal Investigators

  • Christopher Kenney, MD · Biotie Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-01-12
Completion
2018-01-12

Countries

  • United States
  • Austria
  • Canada
  • Czechia
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02453386 on ClinicalTrials.gov